Mitochondrial Thioredoxin System as a Modulator of Cyclophilin D Redox State [PDF]
, 2016 The mitochondrial thioredoxin system (NADPH, thioredoxin reductase, thioredoxin) is a major redox regulator. Here we have investigated the redox correlation between this system and the mitochondrial enzyme cyclophilin D.
Bindoli, Alberto +7 more
core +1 more source
A conceptually new treatment approach for relapsed glioblastoma: Coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care. [PDF]
, 2013 To improve prognosis in recurrent glioblastoma we developed a treatment protocol based on a combination of drugs not traditionally thought of as cytotoxic chemotherapy agents but that have a robust history of being well-tolerated and are already marketed
Adnot +307 more
core +4 more sources
Gold amides as anticancer drugs: synthesis and activity studies [PDF]
, 2013 Modular gold amide chemotherapeutics: Access to modern chemotherapeutics with robust and flexible synthetic routes that are amenable to extensive customisation is a key requirement in drug synthesis and discovery.
Amagai +34 more
core +1 more source
Auranofin prevents liver fibrosis by system Xc-mediated inhibition of NLRP3 inflammasome
Communications Biology, 2021 Using mouse models of liver fibrosis, Kim et al examined the mechanisms underlying the antifibrotic inhibition of the NLRP3 inflammasome by auranofin. They demonstrated that auranofin-induced inhibition of the NLRP3 inflammasome in bone marrow-derived ...
Hyun Young Kim +10 more
doaj +1 more source
Understanding cisplatin resistance using cellular models [PDF]
, 2007 Many mechanisms of cisplatin resistance have been proposed from studies of cellular models of resistance including changes in cellular drug accumulation, detoxification of the drug, inhibition of apoptosis and repair of the DNA adducts.
Davey, Mary W., Stordal, Britta
core +2 more sources
Cytosolic thioredoxin reductase 1 is required for correct disulfide formation in the ER [PDF]
, 2017 Folding of proteins entering the secretory pathway in mammalian cells frequently requires the insertion of disulfide bonds. Disulfide insertion can result in covalent linkages found in the native structure as well as those that are not, so‐called non ...
Elias SJ Arnér +8 more
core +2 more sources
Auranofin, a thioredoxin reductase inhibitor, causes platelet death through calcium overload
Platelets, 2019 Platelets are central to normal hemostasis and must be tightly controlled to prevent thrombosis. However, drug treatments that also affect platelets could lead to unwanted side effects on hemostasis or thrombosis.
Matthew T. Harper
doaj +1 more source
In Vitro Investigation of Auranofin as a Treatment for Clostridium difficile Infection
Drugs in R&D, 2020 Background Clostridium difficile infection is the leading cause of hospital-acquired gastrointestinal infection and incidence rates continue to rise. Clostridium difficile infection is becoming increasingly complex to treat owing to the rise in treatment
Christine Roder, Eugene Athan
doaj +1 more source
Virulence, 2021 The slowing-down de novo drug-discovery emphasized the importance of repurposing old drugs. This is particularly true when combating infections caused by therapy-refractory microorganisms, such as Scedosporium species and Lomentospora prolificans. Recent
Hajar Yaakoub +6 more
doaj +1 more source
Will Auranofin Become a Golden New Treatment Against COVID-19?
Frontiers in Immunology, 2021 Auranofin is an FDA-approved disease-modifying anti-rheumatic drug that has been used for decades for treatment of rheumatoid arthritis. This gold(I) compound has anti-inflammatory properties because it reduces IL-6 expression via inhibition of the NF-κB-
Karine Sonzogni-Desautels +4 more
doaj +1 more source